Publications by authors named "R M GRAINGER"
Objectives: There is no guidance to support the reporting of systematic reviews of mobile health (mhealth) apps (app reviews), so authors attempt to use/modify the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). There is a need for reporting guidance, building on PRISMA where appropriate, tailored to app reviews. The objectives were to describe the reporting quality of published mHealth app reviews, identify the need for, and develop potential candidate items for a reporting guideline.
View Article and Find Full Text PDFClimate change and pollution are a major existential threat. Healthcare contributes a noteworthy 4-6% to the total carbon footprint and 5-7% of the total greenhouse gas (GHG) emissions. Environmental pollution and modern lifestyles are also contributing to the increased prevalence of autoimmune and lifestyle-related rheumatic disease.
View Article and Find Full Text PDFAims: The essential components of a rheumatology service for public hospital rheumatology services in Aotearoa New Zealand are not yet defined. We aimed to seek the views of users of public hospital rheumatology services on potential components of a rheumatology service.
Methods: Online survey of adults in Aotearoa New Zealand who self-reported as having used district health board rheumatology services in the past 5 years.
Objective: Little is known about the preferences of people with rheumatoid arthritis (RA) regarding tapering of biologic disease-modifying antirheumatic drugs (bDMARDs). The aim of this study was to assess the preferences of people with RA in relation to potential treatment-related benefits and risks of bDMARD tapering and the health care service-related attributes that affect tapering.
Methods: Participants with RA who had experience taking a bDMARD completed an online discrete choice experiment.
Article Synopsis
- - The audit investigates how long it takes patients with newly diagnosed seropositive rheumatoid arthritis (RA) to start disease modifying drug (DMARD) treatment and whether this timing meets the recommended 6 weeks.
- - Data from 355 patients showed that 64.8% started DMARD treatment within the target timeframe, with significant correlations to rheumatologist staffing levels and the rurality of the patients.
- - The study concluded that variations in the time to DMARD treatment are largely influenced by the number of rheumatologists available and the geographic location of the patients, rather than factors like ethnicity or socio-economic status.